[Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide].
|
| Abstract |
Cardiovascular risk reduction is the major aim of type 2 diabetes mellitus treatment. The effects of various antidiabetics on the cardiovascular complications are currently under careful scrutiny. Incretin-based therapy that utilizes the effects of glucagon-like peptide 1 (GLP-1) or stimulation of its receptor by GLP-1 receptor agonists represents one of the most promising approaches from the potential cardiovascular risk reduction point of view. Experimental studies have shown that the GLP-1 and GLP-1 agonists treatment improves endothelial function, decrease blood pressure and protects myocardium during experimentally-induced ischemia. Clinical studies with GLP-1 receptor agonists consistently show that, in addition to good antidiabetic efficacy, its long-term administration decreases blood pressure, body weight and improves circulating lipid levels while slightly increasing heart rate. In this paper, we focus on the cardiovascular effects of GLP-1 receptor agonist liraglutide. Preliminary analyses of cardiovascular complications in phase III trials with liraglutide indicate its good cardiovascular safety. A possibility of cardioprotective effects of liraglutide remains still open and is currently studied within a prospective cardiovascular trial LEADER.
|
|---|---|
| Authors | Martin Haluzík, Pavel Trachta, Miloš Mráz |
| Journal | Vnitrni lekarstvi (Vnitr Lek) 2015 Jul-Aug Vol. 61 Issue 7-8 Pg. 635-40 ISSN: 0042-773X [Print] Czech Republic |
| Vernacular Title | Kardiovaskulární účinky léčby GLP-1 agonisty se zaměřením na liraglutid. |
| PMID | 26375689 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!